Careers: Join Our Team

 

Vice President, Clinical Operations

Position Summary:

At Aditum Bio our mission is to give patients access to medicines that may not otherwise be developed. Co-founded by industry veterans Joe Jimenez, former CEO of Novartis, and Mark Fishman, former President of the Novartis Institutes for Biomedical Research, the firm in-licenses promising therapies that for some reason are not advancing toward the clinic. Aditum Bio focuses on the translational phase of medicine (Phase I and Phase II) to generate data that can support full clinical development, and eventual market launch, to reach patients in need. 

The VP of Clinical Operations is responsible for leading the overall planning, oversight and execution of Aditum Bio companies’ clinical trial programs in all phases of development (I-III).  This includes the strategic planning of the clinical program with Aditum Bio and portfolio company teams, as well as executing together with our strategic partners and CROs.

Position Responsibilities:

  • Clinical Operational Planning and Collaboration: Collaborate with the Aditum Bio portfolio company teams to closely plan clinical trials, ranging from Phases I-III across therapeutic areas. Develop the clinical operations framework for Aditum Bio companies. Partner with and maintain regular contact with key stakeholders including Medical, Regulatory Affairs, Quality Assurance, Legal, Finance, and Program Management.

 

  • Program Execution and Oversight: Oversee the tactical implementation of the clinical development plan for all assigned clinical programs, managing the site contracts, budgets, timelines, clinical trial vendors, CRO resources, patient enrollment and site activities. Identify and mitigate risks to study implementation, enrollment, conduct, compliance, and completion. Attend partner and vendor meetings to ensure alignment and achievement of study goals.

 

  • Partner Collaborations: Drive the establishment of key strategic partners across Aditum Bio companies based on phase, budget and timelines for clinical development. Manage the relationship with our external partners, ensuring that the interests of the companies are protected.

 Qualifications: 

  • BA/BS in science (e.g., biology, chemistry, pharmaceutical sciences) 

  • Pharmaceutical industry experience (minimum 10 years) guiding new drug clinical development/operations program for both small molecule and biologic drug candidates

  • Strong leadership skills with ability to be hands-on and lead/ manage the clinical program

  • Thorough knowledge of the clinical development process, FDA, EMA and other regulatory requirements that may impact global clinical studies as well as ICH and GCP guidelines

  • Success identifying, negotiating and overseeing outsourced clinical operations services and vendors

  • Strong track record in effectively working with senior management

  • Proven ability to work collaboratively internally and externally, with the ability to manage multiple stakeholders

  • Results oriented and self-assured. Ability to push timetables while keeping the team motivated 

Company Overview:

 

Aditum Bio is a new model of biotech venture capital uniquely positioned to rapidly translate scientific discoveries into innovative new medicines. Aditum brings together unmatched scientific and domain expertise, combined with operational capabilities. Our agile operating model enables rapid company formation, planning, and execution for a new model of drug development. We target clinic-ready therapies to help underserved patient populations, rapidly forming companies and staffing them with medical and scientific experts. Launched in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, Aditum currently manages a broad portfolio of clinical stage companies with multiple drug candidates entering Phase 2 clinical trials in 2022.

Aditum Bio provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.